Hey everyone, this is Dan. Moderna and BioNTech each drop more than 10% from June 14th to June 16th. They have been recovering. What caused the drop? Where would they go in the next three weeks? Let's go over the details. May 28th, when I published my last video on the subject matter, I predicted Moderna to be at $200 a share and BioNTech at $230 a share by the end of August 2021. At a time, Moderna was at 185 and BioNTech at 204, quite a distance from my targets. And so yesterday, market close, Moderna was at 208, exceeding my target and BioNTech at 226, almost at my target. Just want to give you a preview. My new forecast is that Moderna will be at $220 a share and BioNTech at $250 a share by the end of September 2021. In the next few minutes, I'll be talking about the most important news that happened in the last few days and the new COVID cases in the US, UK, Israel, India and worldwide. I'll talk about the valuation of these two companies and I'll be comparing the different vaccines available in the market. Then finally, we will go into the charts and look at technical analysis. First of all, on June 14, Novavax said its COVID vaccine is 90% effective and they plan to submit the data to FDA in a third quarter for emergency approval. And that caused a major shock wave in the stock market as far as COVID vaccines are concerned. As you can see, we start from the Friday before June 14, which was a Monday. And then on June 14, the news here broke out and the stock price for BioNTech and Moderna dropped quickly. And by the time it was June 16, BioNTech closed 14% below the June 11 price. Moderna closed almost 10% below the June 11 price. Intraday, both of them got even lower. And finally, they started to recover. May 6, Novavax announced that they reached agreement with GAVI, which is an organization for procuring COVID vaccine for developing nations. And Novavax is supposed to deliver 350 million doses beginning third quarter of 2021. They will ultimately deliver 1.1 billion doses of vaccines to COVAX. In the meanwhile, another vaccine that's being in development, CuroVac, failed in the phase three trials with only 47% efficacy. Moderna signed an agreement with UNICEF to provide 34 million doses of vaccine in the fourth quarter of 2021. And they have the option to supply up to 466 million doses in 2022. And then on June 16, it was announced that the US government purchased additional 200 million doses of Moderna vaccine. So far, the US has purchased the total of 500 million doses. BioNTech on June 10 announced that they will provide 500 million doses of vaccine to the US government for donation to the poorest nations in the world. One thing Ruthie mentioned is that the US government purchased the vaccine at not-for-profit price. And then earlier in May, BioNTech received the first authorization in European Union for the vaccine to be used on adolescents ranging from age 12 to 15. And that was on May 28 when it got the interim approval. In my last video, I showed this particular table indicating how many different doses have been under contract for 2021. You can see that if you add up all the vaccines that have been committed for 2021, it will cover 55% of the world population. That's not including Novavax, because at that time Novavax was still in phase three trials. Now with the positive result announced from Novavax, if we were to include the dosage from Novavax, the number of doses under contract by all these companies will already cover 64% of the world population for 2021. For 2022, we already know there will be additional production capacity from BioNTech and Pfizer covering 4 billion doses. And Moderna announced a total of 3 billion doses for 2022. And then Novavax recently signed a contract with COVAX for 1.1 billion doses. If you add up these new numbers with the 2021 numbers, we will see that the number of doses under contract for 2022 will cover 87% of the world population excluding Novavax. And including Novavax, it'll actually cover 102% of the world population. That will be more than enough. And that's why the whole discussion about waving vaccine pattern is a move point, because the leading vaccine makers already aggressively line up production agreements around the world to ensure that there will be enough supply for the entire world, and they've been selling the vaccines to the developing nations and not for profit prices. In the meanwhile, the reasonably high prices for the vaccines are still protected for developed nations. And that's good news for the stock owners of Moderna and BioNTech. If you like what you've seen so far, I'd like to encourage you to click the like, subscribe, and notification button. That'll encourage me to make more videos like these, and also it will help the YouTube algorithm to direct more viewers to my channel. Thank you very much. Let's continue. I've been showing this vaccine comparison slide in my previous videos from Moderna and BioNTech, so I don't want to go over every single point. If you want to look at the details, you can do a screen capture of this. The gist of it is that we have all these different vaccines already available in the market. And then for this video, I added Novavax, which is a two-dose vaccine, selling for about $16 per dose, and it will probably get approval in the fourth quarter of 2021 from both the US FDA and from EU. But overall, Moderna and BioNTech are still the best defense against COVID-19, although Novavax is a fairly close competition, so I'll be watching the development from Novavax very closely. Let's look at the COVID cases in the United States. So far, 53.4% of US population have already received the first dose, and 45.2% of the population have already been fully vaccinated. The number of daily new cases has been going down dramatically. The US uses the BioNTech vaccine, the Moderna vaccine, and some Johnson and Johnson vaccines. Let's look at Israel. They have 60.7% of the population having received the first dose, and 56.9% of the population who are fully vaccinated. The case count has been zero for the last couple of weeks, and that's a very good development. They've been using primarily BioNTech and a little bit of Moderna vaccine. Let's look at UK. It's a little bit different story, even though they have 64.6% of the people receiving the first shot, and with 47.1% of the population fully vaccinated. But you can see that the case count has been creeping back up in the last two, three weeks, and it's approaching 10,000 cases a day, which is pretty substantial. And they've been using the BioNTech vaccine with AstraZeneca, and these two are the primary vaccines they use, and they also use a little bit of Moderna, and recently they also approved Johnson and Johnson. The good news is that the death rate has been still very low. That means, even though more people have been testing positive recently, that the infections have not been fatal. Why is this happening? Why are more people getting infected? There's an article on Markowitz that talked about the Delta variant, which was the variant first discovered in India. Apparently, this particular variant is a lot more contagious than the original variant. It looks like the newly infected are mostly the younger people who are less likely to have been vaccinated, and that's why they've been getting sick. In the meanwhile, they found that 99% of new cases in the UK belong to the Delta variant, whereas in the US, only 10% of the new cases belong to the Delta variant. That could be foreshadowing what's going to happen in the US, but let's hope that then we will find a way to contain the Delta variant effectively in the US and in the rest of the world. Let's look at India. For a while, India was in pretty bad shape, as you can see back in March and early April, the case count was climbing very quickly and reached a peak of about 400,000 new cases per day, but in the last few weeks, it's been going down dramatically. The interesting part is that they only have 16.7% of the population having received the first dose, and only 3.8% of the population having been fully vaccinated. So what's causing the drop? Actually, I've been doing the research and still I don't have a full answer yet. At this point, I've got to be honest with you about that. Oh, by the way, so far, India has been using the AstraZeneca vaccine, and the Covaxin made in India as well as a Russian Sputnik 5 vaccine, which was approved recently. It was this BBC article saying that it appears that the vaccine, it appeared that the COVID cases have peaked in certain states, but it's just starting to grow in some other states. And also because the infection is mostly now spreading in the rural area, it's not easy for them to get the accurate case count. One possibility is that maybe the virus has burned through a large part of the population already and therefore causing herd immunity in some parts of the country. So far, it's too early to tell exactly what's going on, but let's just be happy that the daily case count has been going down. But I don't think we're at a point where we are saying that we don't need vaccines anymore. I still believe that the world needs more vaccines to be produced by companies such as BioNTech and Moderna, and that's why I believe the two stocks are still going to be pretty strong. Now if you look at the worldwide daily new cases, even though it's been going down, but the most recent count is still more than 279,000 new cases a day, that's still pretty serious, and that's why the world still needs more vaccines. Let's look at the professional analysts' opinions about these two companies. Now I'm comparing today's ratings with the ratings back on May 28th when I published the last video. Of course, yesterday's closing price was $208, and today actually the price picked up a few more dollars already. And my target is at $220. Yahoo Business didn't change a high rating still at $246, but increased the average rating from $178 to $181, and the low rating remains at $83. Lewis Nivellia has maintained his overall A rating, which is a strong buy, and he upgraded the fundamental rating from C to B. TipRanks.com gives them a moderate buy, increased the high rating from $231 to $246, they increase the average target from $177 to $194, and maintains a low target of $100. CNN Money maintains a buy rating, the high target got increased from $231 to $246, medium remains the same at $190, and low target remains the same at $83. For BioNTech, the closing price yesterday, June 21st, was $226. As of now, the price already picked up a few more dollars, that actually at $235 at around 2 p.m. on June 22nd, went up $5 already from yesterday. Yahoo Business' high target is $237 unchanged. Average target went down from $195 to $193, and the low target remains at $108. Lewis Nivellia, overall rating A, strong buy, and the fundamental rating got improved from C to B. TipRanks.com is still a moderate buy, the high target is still at $240. Average target went down a little bit from $186 to $182, and the low target remains at $133. CNN Money does not offer any forecast for BioNTech. Let's look at my own valuation. This is the valuation I showed in my May 28th video. First of all, I took the average PE ratio from the top pharmaceutical companies. I determined that the average PE ratio of 12.4 is a reasonable number to use for Moderna and BioNTech, and I assume a net margin of 33%, which is a net margin for Regeneron. And based on a 2021 confirmed contract and the number of doses they expect to sell for the next two years, I arrived at the stock price of $200 a year. As you can see, $200 a year is a very conservative number, looking at my calculated numbers here. And recently, because Moderna announced that they were getting ready for 3 billion doses of production in 2022, and my calculation was based on only about 1 billion doses. With the additional contract announced with the US and other countries, I think the number would definitely go up, and that's why I'm increasing my targeted $200 a year. Let's look at BioNTech. This is the calculation I showed back on May 28th. Again, I used the average PE ratio of 12.4, 33% net margin. And then based on the existing contract and what they expect to produce in 2022 and beyond, which is 4.0 billion doses, then I arrived on May 28th, my target of $230 a year. Again, this was a very conservative estimate compared to my calculated numbers. At this point, because of the positive developments, I'm increasing my target to $250 a year to be reached by the end of September 2021. Let's look at the charts. This is a daily chart for the last six months. The candlestick chart is Moderna. The yellow line is BioNTech, and this red line is SPY, reflecting the standard input 500, and QQQ, reflecting the NASDAQ 100. As you can see, both Moderna and BioNTech have outperformed the broad market, and with BioNTech going up 112% in the last six months, and Moderna going up about 50%. For the three-month chart is Moderna, BioNTech, SPY, and QQQ, still BioNTech outperform Moderna, and both of them outperform the broad market. If you look at the last 30 days, looks like Moderna has overtaken BioNTech, and both of them are still very impressive compared to the broad market, and that's why I'm so bullish about these two stocks. Let's deep dive into BioNTech. From this daily chart, you can see that it's been making higher highs and higher lows. Definitely, that's a very bullish trend, and on June 14, the news about Novavax knocked it down a little bit, but it started to recover. We see this overboard warning signal from RSI back in the beginning of June, and so far the RSI is within reasonable limits. DMI just flashed a buy signal as of yesterday, and MACD so far is still in the bearish zone. Hopefully, it'll turn bullish and flash a buy signal pretty soon. Let's look at a short interest ratio. As of yesterday, market closed, the short interest ratio was less than 10%. That's very low. If you look at historically how the short interest ratio correlated with the stock price, we can see that whenever the short interest ratio got below 12%, then we had a high probability of hitting a short-term peak, then the stock price would drop a little bit and then recover after a few days. We're at a point where people might start to take profit soon. That's why I'll be watching my BioNTech Moderna holdings very carefully, and I'll sell when it starts going down again. Then I will buy back the shares at a lower price later. If you look at the hourly chart, then we can try to see where the support and resistance levels are. And by the way, I bought more shares of BioNTech as of yesterday morning before market open. Actually, I bought at about $215.30, and since then it's gone up quite a bit already. I also sent out the text message from my tutor account saying that I bought BioNTech. So if you're interested, please subscribe to my Twitter account. That way you can receive my instant updates when I make major trades or maybe when there's major development related to the stocks that I track by way of my YouTube videos. Let's look at the support points. I see support at 216, which is right here. And that coincidentally is also the 20-day simple moving average. So that'll be a very strong support point. The next level down is 211. Here in the next level down is 206. And then the next level down is 188, which is a lower bonus demand for the next couple of days. For resistance, I see the next level 227, which was actually around the closing prices of yesterday. And of course that has been penetrated. So we're definitely above that already. The next level up will be 235 here. The next level up 242. And then next level will be 247, which is the upper bonus demand for the next couple of days. And then of course 252, which is the all-time high. Let's look at Moderna. This is the daily chart. We see Moderna making higher highs and higher lows. That's a very bullish pattern. And it came down and then started to turn upward as of yesterday and this morning continued to go up. We saw the overbought signal here from ISI pretty much in the beginning of the month, but now it's within reasonable range. DMI, flash buy signal, MACD, similar to BioNTech is still in the bearish zone, but today it will probably turn positive by the time the market closes. Let's look at a short interest ratio similar to BioNTech. It's at a very low point, about 11%. And historically whenever we have such a very low short interest ratio, we have a high probability of hitting a short-term peak and then the stock price would drop for a few days before it recovers. That's why I'm very careful about watching the stock price and I'll be ready to sell some of my shares to lock in my profit when it starts dropping in the next couple of days. Let's look at the support and resistance levels for Moderna. In my last Moderna video, I used this Fibonacci extension drawing and it turned out to be quite accurate for predicting these critical points for the stock price. This point is the maximum for the Fibonacci extension chart and this point is the minimum for support levels. The next one is 201 which is right here at 23.6% Fibonacci extension and the next level down is 189 that was this peak achieved on around March 4th and then the next level down is 174, next level down 161 and then 147. For resistance levels, the next level is 208 which was the closing price yesterday and actually the price penetrated that level. It's heading towards the next resistance level of 213 which is at about 38% Fibonacci extension and the next level up will be 219 and that's the 50% Fibonacci extension. The next level up is 227 which is the all-time high achieved in the beginning of June and the next level up is 237 100% Fibonacci extension. I'd like to encourage you to subscribe to my Twitter account because if there's any major news that breaks out that might affect the stock prices, I will either post an updated video or if I don't have time to post an updated video, I will send out some information by way of my Twitter account. As usual, you can send me your comments, questions and suggestions by way of my Twitter account as well as my YouTube channel. If you like what you've seen, I'd like to remind you to click the like, subscribe and notification button. Thank you very much. Let me recap my price targets. I expect Moderna to be at $220 a share and BioNTech at $250 a share by the end of September 2021. What are my strategies in light of what we've seen so far? I will buy Moderna or BioNTech when the price pulls back at the peak by more than 5% to 10% and find support. That was exactly what I did yesterday when I bought BioNTech and I sent out a message from my Twitter account to my subscriber notifying them that I just bought BioNTech and the reason why I bought it. And the price drops significantly due to news events. I will update my fundamental analysis and we'll post new video or if I don't have time to produce a new video, I will send Twitter updates to my subscribers. I will definitely continue to monitor the short interest ratios because I believe the short interest ratio is a little bit low at this point. People are prone to do profit taking when the short interest ratios are this low. And that's why I expect a little bit of a price drop for both stocks in the next 2-3 days. As usual, I will not pump the stocks relentlessly just because I own them. There are times in my videos that I tell my subscribers that it's not time to buy any more Moderna or BioNTech stock that they should just wait until the price starts to recover. In the meanwhile, if I do sell my stocks to lock in my profit, I will send out Twitter messages to notify my subscribers. I'd like to remind you that I'm not a financial advisor. I share my stock trading strategies for educational purposes only. You should make your own decision with regard to buying or selling stocks and you should definitely consult with your financial advisors before you do so. Well, this is about the rest of my video for now. I will chat with you again in the next few days. In the meanwhile, I'd like to wish you the best of luck with your financial investments. Have a wonderful day.


This is stock number 9J178A. We are here at Summit Automotive in Fond du Lac, Wisconsin. You're new and used Jeep and Jeep Cherokee headquarters. Today we are checking out this Super Clean 2019 Jeep Cherokee Limited. This vehicle has the 2-liter turbocharged 4-cylinder motor, which pumps out 270 horsepower. This vehicle has been fully safety and inspected by our service shop, has a fresh oil and filter change. All the fluids have been checked and topped off. And this Jeep is 100% ready to go. Bright white is the color. We shoot all of our videos in 1080p, 60 frames per second. So if you have HD capabilities on your computer, tablet, or smartphone device, turn them on right now because it is like you're right here looking at the vehicle with me. And definitely your best way to check out the vehicle quality and condition wise before seeing it in person. If you want to check out more photos of this vehicle in the upper right hand part of your screen, there's a link right to our website. So click that and check us out there to see all the photos. Comes with the 18-inch painted and polished aluminum rims, Continental Pro Contact 22560R18 tires with probably about 80-90% of the tread left on there. Didn't see any dents or dings on that front fender. You get the LED headlamps, the LED running lights, and the LED fog lamps. Front bumper is in excellent condition. I didn't see any dents, dings, or cracks on that. And the hood is in excellent shape as well. The limited package gives you the chrome-trimmed Jeep lettering, as well as the chrome-trimmed grille inserts on the seven-slotted grille. Passenger side rim is in excellent shape as well. No scuffs or scrapes on that. And as you go down this side of the vehicle, you can see just how clean the body is, how reflective and mirror-like that paint is. We take these HD videos, so if you are far away, or even if you're close by and just cannot make the trip down, but you're still interested in purchasing the vehicle, you can see the vehicle, hear the vehicle, and have confidence in what you're looking at before you even get here, so that you can make a smart buying decision from the comfort of your own home. That's why we offer the Summit Auto Fastpass option in the upper right hand part of the screen, a link right to our website where you can apply for financing, get pre-approved, see a payment quote, even appraise the trade all from the comfort of your own home. So that when you get here, all you got to do is drive the vehicle and love it. You'll be all set to go. Back tires are just as new as the front tires. In fact, these tires have just about all the tread left. Still have little wear knobs on there. Four-wheel disc brakes on this vehicle. You do get the dual rear exhaust, the backup parking sensors, and the backup camera with the limited package, the chrome 4x4 limited and Jeep lettering on the back. This is a power lift gate. Back storage area is very, very clean. And because it's a four-wheel drive, this one's going to come with a spare tire and jack tools. Those seats do fall down for extra storage. And to get this rear gate down, you just press this button right here. It'll beep at you three times and then come on down. Actually beeps at you a total of four. And notice the LED license plate lights, as well as the LED tail lamps there. And down this side of the vehicle, just as clean as that passenger side. Back rim, no scuffs or scrapes on that. Didn't see any dents or dings on the quarter panel here. And the driver's side doors are in excellent shape. Now it does have the entering ghost system, so you just have to have the key fob in your pocket. It'll automatically unlock. Also has blind spot and cross-path detection monitoring. LED lights in the mirrors, as well as them being heated mirrors. Inside the limited package gives you the light gray leather interior. No rips, no tears on the seats. Very nice and clean. Both these seats are heated. Power driver seat, power passenger seat, factory floor mats throughout, auto headlamps, power windows, power locks, power mirrors, and memory driver seat. As you hop inside the vehicle here, you can see that this one has only 6,578 miles digital speedometer, range to empty, and a compass display, as well. Comes with the heated leather wrap steering wheel, cruise controls on the right, Bluetooth and information center controls on the left, audio controls on the back of the steering wheel. Comes with the 8.4 4C radio, which gives you AMFM and Sirius XM radio capabilities. You can also do your climate control here as well. Dual climate control, you can also do your heated seats and heated steering wheel buttons there. Also has a backup camera with dynamic grid lines, meaning that those guys turn as you turn the steering wheel so that you can see where the vehicle is going to be headed in the future there as you're backing up. The other thing with this radio gives you Android Auto and Apple CarPlay capabilities. You have your backup parking sensors that you can turn off there. Dual climate control, you can control your climate control down here as well. If you don't like the radio buttons, the more tactile and the knob here, some people like that better. Stability control, and that's your start, stop capabilities. You can turn those off. This is a four-wheel drive, so you get the active drive one system with the auto snow, sport, sand, and mud options on there with the select terrain. Just turn that dial and it'll change whatever terrain settings you want. Augs and a USB jack, and then the nine-speed automatic transmission. Passenger side seat and floor mat are in excellent condition as well. No rips or tears this vehicle has never been smoked in and was locally driven since new. Has the power vista roof, well the power front sunroof, and then the second row fixed glass. Home link buttons for your garage door security systems and lighting systems, map lights, and your dimming mirror. We'll take a quick look at the back seats, and then we will check out under the hood. Back seats are just as clean as the front seats. No rips, no tears back here. Latch child safety system, never any pets back here. Has two USBs, two USB C's back here, as well as a 115 volt, 150 watt plug-in. Factory floor mats, and these seats do fall down for extra storage and they go down really nice and flat, so if you gotta put a bunch of stuff in the back it goes pretty easy. You also get a cup holder in the center console for your back seat passengers. You do get the child safety locks in the back door, and we'll take a quick look under the hood. I would personally like to thank you for checking out the video today, and hopefully from this HD video you will have been able to tell just how clean this Jeep is all the way around. Inside note, under the hood we have the two-liter turbocharged four-cylinder motor. 270 horsepower engine base, very clean, runs very smooth. This Jeep has been fully safe and inspected by our service shop has a fresh oil and filter change. All the fluids have been checked and topped off. The vehicle has been gone through mechanically 100% and is 100% ready to go. I'd highly recommend it from a quality and conditioned standpoint. And to see more pictures of this Jeep or one of our other 450 new and used cars, trucks, SUVs, minivans, wranglers, halftones, recorder tons, one-tons, you name it, we got it, go to our website, www.summitauto.com. Full pictures and descriptions of every single vehicle from two locations all at summitauto.com. And if you'd like to check out more HD videos you can go to youtube.com slash summitauto. Remember to like, subscribe, and share on this video and all the videos that you see there. In fact in a second you will see a link to subscribe to our YouTube channel. On your left a link to more used inventory videos like this one on your right. If you have not been to our website on the bottom link to this vehicle on our website click those check us out and we really look forward to helping with this super clean like new 2019 Jeep Cherokee Limited 4x4. Thanks again.


Welcome back to the second channel. Thank you for joining me here today. I'm gonna be doing a video about Andy Negative. He's TikTok's latest sensation, and by that I mean, I actually don't know if any of you will have heard of this guy before. Before sitting down to record this video, I kinda thought that this guy was like another one of those TikTok-wide phenomenons that everybody knows about and is talking about, cause he's showing up on all of our 4U pages. Cause he's been showing up on my 4U page every day for the past few months. But while sitting down to start recording this video, I started looking through his TikToks and realized that I think his most liked TikTok only has like 6,000 likes. I'm actually starting to feel like it's just me that is in this like weird niche of like bad pop punk music on TikTok. I don't even know what niche this is. But I wanna talk about this guy cause I think it brings up a lot of important topics for social media influencers like me and Andy Negative. Who's this guy on the screen right now? This is who we're talking about. Quite honestly, I think that Andy Negative needs my help. So I'm here to help him. Andy, if you're watching this, please take some notes. Okay, so this is the first TikTok that thrust Andy into the spotlight. And by spotlight, I mean, this video has 4,000 likes and 400,000 views, which is not a great ratio. So that'll give you an idea of what we're about to watch. Did I just write the next emo anthem? We are the princes and princesses of the glory days. We were raised on a train. Yeah, he starts the TikTok off by saying, did I just write the next emo anthem? TikTok answered with a resounding no, unfortunately. As you could probably guess from listening to the song, it was not well received on TikTok.  This has 16,000 likes and this video only has 5,000 likes. Just says no, you did not write the next emo anthem. I mean, personally, I'm not like that into the emo music scene. So like when I saw this, I guess I was probably like, this song is kind of corny, but like, you know, I'm not really into that scene in general. So I'm like, I don't know if people like this. Maybe, I mean, people like corny music or people out there that like corny music. So I didn't think it would be like completely negatively received, but I literally don't think I've seen one nice comment about this song. We've got comments like, yo, unreleased this with fire emojis. People saying, is this satire? People labeling the song as Disney rock. Over the course of the next couple of days, Andy continued to promote his song in pretty much the same way. He has another TikTok that says, this song is for all the weird kids that ever felt left out. Which if you know anything about me and you watched my video about the Kyle Shealy situation, you know I really love it when people identify as being weird and people describe themselves as being kind of a weirdo. I really love that. That's like one of my favorite things. People were commenting on his TikToks, giving him hate. People were duetting him, giving him hate. This TikTok has 133,000 likes. I just wrote the next emo anthem. Let's check. No, but yeah.  And you know what? Sure, it's not a great song. But like, I do think that the hate on him is a little bit unjustified. Or at least it was at first. Like TikTok's just trashing this dude, calling him pellet gun Kelly. I mean, making fun of the way he enunciates words. The creator of this TikTok said, the way he enunciates words makes my brain itchy. And I kind of just felt bad for the guy. Like he didn't really do anything that wrong. He just made a corny song. And you know, I know that I make fun of people basically every week on my channel. I think maybe the difference here is there's like not even that much to make fun of. It's like he just wrote a bad song. It's not even that funny. So I think that's why it feels different to me. Not to mention like all of the hate comments on his videos are so unoriginal. I do find it kind of ironic that like people are commenting on this dude hating on him for being like generic and corny, but like half of the comments on his videos are yo, unrelease this with fire emojis.  Someone commented, we know it's you under there, Danny. Are there people that think this guy is me? To that point, I guess, of people thinking that this might be me doing some kind of joke. There are people that think that this is satire. Oh, we could go.  And that was wrong. This is a real song and a real man. So my bad. This is something I actually kind of go back and forth on. Whether this guy is doing some sort of satire routine or if this is like his actual self. I heavily lean towards this is who he actually is.  If you scroll down, this is at the very least a long con because he's been making videos as the same type of person since, I guess the beginning of 2020. And I think he has a YouTube channel too. Okay, he's been making videos on his YouTube channel for six years. Sunday Fun Day question, Mark? Go ahead and check that out. Hey guys. So it's 10 a.m. on a Sunday, which is really early for me. Usually I don't get up at 10 a.m. I was bartending last night. Okay, so this is kind of weird. I do feel like he's giving off like a slightly different persona in this video. Maybe it's because he just woke up. But I do feel like in his newer videos, he's a lot more like, turns out I just made a Disney pop song. I just made the new emo banger. And then in this video from six years ago, he's like, what's up guys?  Okay, let's look at like this song from five years ago. Let's see if it's similar at all in style. Did you ever stop to think that this world isn't half the world you thought that it could be? Okay, still not really my cup of tea and it did seem a little bit corny, but now I don't know. Like it does seem different. It's like a little darker maybe. Maybe it's just because it's acoustic. The people who are saying Disney, whatever, Disney, pop punk, that is very much the vibe I'm getting from the newer stuff. To be fair, I haven't listened to the whole song. Maybe I should do that first. It's gonna be, it's gonna be, it's gonna be, it's gonna be, it's gonna be, we could be anything we want. Well, we wanna have a good time. Is that too much to ask? Just change genre's mid-song. Okay, there's something weird going on where without this video that he puts at the end of all of his TikToks of him doing the song, without this, it's actually not as bad. I think it might just be like watching him sing that is part of the problem. Yeah, this definitely isn't helping for sure. This is how I recorded the vocals for when we were young. We are the princes and princesses of First, I set up a blanket. Oh, I thought that was gonna be the whole thing. I recorded the vocals, basically just stood in front of a microphone and I sang. This is the Apex 460. Oh man, he's got a poster of the Joker in his room.  It's not easy to defend you, my guy, but I'm gonna try it, all right? We're gonna flip this around. We don't need to be so mean to this guy. Honestly, the song, if you give it a listen, it's not that bad without him performing it, I feel like because he's got that cringy emo aesthetic that a lot of people think is cringy. Of course, watching him perform the song is going to make it worse, but without him performing it, it was not as bad. Still not something I would listen to. And also, I think that the parts that he didn't put in his TikToks are better than the parts that he did put in his TikToks, which is a little suspicious, honestly. And the song also does come off as kind of like nostalgia bait in a way. It's talking about how when we were little, everything didn't seem so bad, but now turns out things are so bad. The real issue that I have with this situation is, one, the unoriginal-ass comments making fun of this dude, just like reposting the same, like, yo, unrelease this over and over. It's like, yeah, I guess it's kind of sad to be promoting a song that everyone hates, but it's also sad to keep checking this guy's profile to see if he posted any new TikToks and then post the same comment that's been getting upvotes on all the other TikToks. But aside from that, it is a little bit weird the way that Andy has responded to the hate that he's been getting. Okay, so this TikTok says, how I sleep at night knowing the emo and punk community think I'm an AI-generated plant sent to destroy the scene from the inside out by releasing music created in a boardroom by business executives trying to water down alternative music until it is absorbed by pop music so they can market it to the general public.  He's got a lot of videos like this that are just like, don't listen to him, dude. Just do you, just be you. Make them cringe, make them say you're awful. Make them tell you to quit because they aren't really talking to you. They're talking to themselves. They're afraid of failure, but you don't have to be afraid. You don't have to be normal, just be you. Which is honestly a fine message. Like if it was, if this was the type of, the only type of response he was posting to the videos, that would be fine. It's like, honestly, I respect that.  It doesn't really matter, does it? But the problem is he posts videos like this. Just be you.  The lyrics don't even rhyme. I feel like guys should address this. Y'all are aware that lyrics don't need to rhyme. The lyrics of the verse are broken up into a four bar stanza. So he goes in to like, in depth on like, rhyming schemes and like, yeah, AB pattern. He also says that actually shirt does rhyme with shit, which it doesn't dude, I'm sorry. These are a perfect rhyme because they're almost the exact same word. They are not a perfect rhyme.  I don't care. I don't know who told you that just cause they have similar letters does not mean they rhyme.  I'm just having fun mentality. If you're then making videos being like, no guys, it does rhyme. So listen, if you just listen to the song the way I want you to listen to it and appreciate it in the ways that I'm gonna tell you to, then it's actually good, that's actually a good song. Please do that. So Andy, if you're listening, this is my advice, okay? You have to pick if you want people to like your music or not. Well, you don't even have to pick that.   No knowledge of rhyme scheme is gonna make people like this song. OMG, this sounds like a kid's song, it's so cringe. Yeah, wouldn't wanna introduce young people to pop punk.  We were young, we were young. Yeah, I love that he ends every TikTok with the same clip of him playing the song.  We were young. Yeah, he's also trying to do this thing here where he's like pretending that that might have been the whole point of this song to begin with. Wouldn't wanna introduce young people to pop punk, which is obviously what I was trying to do here. Again, I'm not trying to be mean, I'm just trying to explain this. When people say that your song sounds like kid's music, that's not because they think it would be good music for kids. They're just saying that it's not good enough to be adult music. It's not a compliment, unfortunately. It's just people being rude. Bro, you gotta stop promoting this song. Why? It's getting tons of views and streams every day. Bro, stop! But you're gonna have to take it up with that.  That's promotion, Andy. What is it doing? Promoting. That's what it was born for. All right, yeah, creepy as hell for sure. And also the whole like, oh, but it's getting tons of views and streams. It's getting tons of views and streams. I don't really feel like it works here. Your music video has 4,000 views and pretty much all of the comments are negative. So I'm sure a few people have found Andy's music that will legitimately enjoy it. There are lots of different people that enjoy lots of different things. So I'm sure there is a market out there for Andy's music, but he is not reaching that market right now. So there is something that he is doing wrong.  So then why are you defending the nauseating amount of promotion you're doing for this song as being like, but it's getting a ton of views and streams. You're not staying consistent with your character, all right? What do you want people to think you care about? It shouldn't be views and streams. I think that there's legitimate hope for Andy. As creepy as that TikTok was, it was a little bit funny. Like if Lil Nas X posted that about one of his new songs, how about how there's this like demonic version of him that is promotion Lil Nas X? I mean, people would think it was funny, right? And it would be funny. I think that he has some like good ideas for promotion. It's just like, you just gotta get like one notch better at making music or finding your audience at the very least. And honestly, that was a lot better than the actual recorded version. So I feel like, you know, there's hope for this guy. He can sing. He goes a little bit too nasally at times for me. But I mean, look at these comments. Look, sounds so much better acoustic. This is actually way better. This is so much better. We are the princess and princesses of the glory days. Even Anthony Fantano is making a song about you. I feel like if Andy can take this and somehow flip it on his head and come out with like a good song that is like, you know, not trying to pander to a certain generation and doesn't sound like a Disney song, he could use this whole meme as like a leaping off point. I think that's totally possible. Andy, I think though that one lesson that would be really helpful for you to learn is something that I've seen a lot of influencers struggle with honestly. And that is that if you're getting hate for something that you're proud of, don't respond to it. Don't ever try to win people over with explanations or anything like that.  Unless you've really hurt a group of people, don't respond to hate.  He's reading my comments and it's having an effect on him. I'm gonna keep doing that. It's like the snowballing thing. There's a reason that certain creators can't seem to get away from drama.  It's because when they get hate, they have to like make a whole video discussing it and going over it. And if it's for something as inconsequential, it's just like, I didn't like this song, just leave it, just don't address it. If it's legitimate criticism, learn from it and just, you know, hit them with the next song, that's better. You're not gonna change their mind with an explanation.  If you are watching this, Andy, which I'm not sure if you will ever see this or make it this far into the video, but look, I mean, it sucks to get this much hate on stuff. I understand that. I hope that you can take my advice to heart. I know that sometimes constructive and well-intentioned criticism can be the most difficult to swallow because you can't just brush it off as someone blindly hating you, but you know, I hope that you are able to learn from this and grow from this. You know, I look forward to seeing your next song. I hope it's good. So, that's all, bye.


the number of reports is similar to the number of cases expected to occur in this age group. The available data cannot determine with certainty if MCV increases the risk for GBS. As a result, no change in vaccine recommendations have been made at this time. CDC now recommends that persons with a history of GBS not receive MCV. However, persons with a history of GBS who are at especially high prolonged risk for meningococcal disease such as certain microbiologists might consider vaccination. Meningococcal conjugate vaccine is a valuable addition to our public health prevention program, particularly for adolescents and young adults. Links to the meningococcal ACIP statement revised recommendations for use of MCV vaccine among children two through ten years of age and other materials are on our updates and resources web page. In June 2006, the Food and Drug Administration approved the license application for the world's first vaccine against cervical and other analgenital cancers. The vaccine produces immunity to human papillomavirus or HPV. In this segment, we want to give you an overview of human papillomavirus, its epidemiology and disease burden and background for the new vaccine. We will then summarize the ACIP recommendations for use of the HPV vaccine. Human papillomavirus is the most common sexually transmitted infection in the United States with millions of new infections every year. Although most infections resolve spontaneously, in a small proportion of people the infection becomes chronic and can lead to serious disease years later. We asked Dr. Mona Soraya, a medical epidemiologist in the CDC Division of Cancer Prevention and Control, to tell us about human papillomavirus, its natural history and its relation to cancer. Human papillomavirus or HPV is a complex group of DNA tumor viruses and is the most common sexually transmitted infection in the United States. HPV infection can be completely asymptomatic and resolve spontaneously or can persist in the infected person and lead to a variety of medical conditions. There are more than a hundred different HPV types. More than 60 of these are characterized as cutaneous types and can lead to skin warts. About 40 types infect the epithelium of the mucosa, mainly the genital mucosa. The mucosal types are further categorized as high-risk types or low-risk types based on their ability to cause cancer.  Low-risk types, notably type 6 and 11, can also cause cervical cell abnormalities that usually resolve spontaneously and do not lead to cancer. Low-risk types can also cause genital warts and a rare condition called recurrent respiratory papillomatosis, a condition in which warts grow in the respiratory tract. It is estimated that more than 6 million new infections with HPV occur every year in the United States and about 20 million people, 15 percent of the U.S. population, are currently infected. Infection with one type of HPV does not prevent infection with another type. 5 to 30 percent of people infected with mucosal HPV are infected with multiple types of the virus. Initial HPV infection occurs soon after sexual initiation and approximately 70 percent of new infections resolve spontaneously within one year and more than 90 percent clear within two years. However, a small percentage of infections become chronic or persistent. It is these persistent infections that can lead to serious illness years or decades later. This graphic shows the natural history of HPV infection, the most common clinical significant manifestation of persistent genital HPV infection is cervical intraepithelial neoplasia or CIN. Within a few years of infection, low-grade CIN called CIN1 may develop, which may spontaneously resolve and the infection clear. Persistent HPV infection may progress directly to high-grade CIN called CIN2 or CIN3. High-grade abnormalities are at risk of progression to cancer and so are considered cancer precursors. A small proportion of high-grade abnormalities spontaneously regress. If left undetected and untreated, years or decades later CIN2 or CIN3 can progress to cervical cancer. In the U.S. effective cervical cancer screening programs are able to detect disease caused by HPV early when it is usually treatable. Persistent HPV infection can lead to cervical cancer years after the initial infection. HPV is believed to be responsible for nearly all of the 12,000 cases of cervical cancer diagnosed each year in the United States. In addition to cervical cancer, other cancers can be attributed to HPV infection as well. This graphic shows the number of cases of select cancers in the U.S. in 2002 and the fraction attributed to HPV types. As I mentioned earlier, among the 12,000 cervical cancers 100% are attributable to HPV.  Of the 4,480 vulvar or vaginal cancers and about 1,000 penile cancers 40% are caused by HPV. Finally, among 10,000 oral and pharyngeal cancers 12% are attributable to HPV. It is clear that human papillomavirus is responsible for a large proportion of the cervical and other analgenital cancers that occur in the United States. However, although there are more than 40 different types of HPV that infect the mucosa, much of this disease burden is caused by only a few types. This graphic shows the proportion of HPV related disease caused by just four HPV types, 16 and 18, which are considered to be high risk types, and 6 and 11 considered to be low risk types. This information is important because these four HPV types are included in the new quadrivalent HPV vaccine. HPV is associated with virtually all cervical cancers and type 16 and 18 are associated with 70% of these cancers. HPV type 16 alone is found in about half of all women with cervical cancer. High risk HPV type 16 and 18 are also associated with 30 to 50% of high and low grade cervical abnormalities and also with the proportion of anal, vulvar, vaginal and penile cancers. In addition, approximately 10% of head and neck cancers are attributed to HPV 16 and 18. Low risk type 6 and 11 are associated with about 10% of low grade cervical abnormalities, but 90% of genital warts and 90% of recurrent respiratory papillomatosis. The American Cancer Society estimates that in 2006 about 9,700 new cases of cervical cancer will be diagnosed in the United States.  Deaths will also occur as a result of other anal genital cancers. About $4 billion will be spent this year on management of sequelae of HPV infections primarily for the management of abnormal cervical cytology and treatment of cervical neoplasia. Disease caused by human papillomavirus is responsible for an enormous amount of suffering, death and medical cost in the United States. The burden of disease is even higher in developing countries where cervical cancer screening programs are inadequate or non-existent. Properly used HPV vaccine has the potential to reduce this burden of disease and save many lives both in this country and throughout the world. The vaccine approved by the Food and Drug Administration in 2006 is called Gardasil and is produced by Merck. The vaccine contains the outer protein called the L1 protein from four types of HPV, types 16 and 18 considered to be high-risk types and types 6 and 11 considered to be low-risk types. Production of the L1 proteins uses recombinant DNA technology similar to what is used for hepatitis B vaccine. The L1 proteins self-assemble into non-infectious units called virus-like particles or VLPs. VLPs are empty protein shells without genetic material. However, they are highly immunogenic and can induce high titers of neutralizing antibody. The vaccine is supplied as a liquid in a single-dose vial or syringe. The vaccine does not contain either antibiotic or preservative. HPV vaccine is intended to prevent cancer, primarily cervical cancer. But cancer can take decades to develop following HPV infection, so a clinical trial using cancer as the outcome is not very practical. Instead, other endpoints were used to determine vaccine efficacy, such as persistent HPV infection, genital warts, and cervical intraepithelial neoplasia, or CIN, which is considered a cancer precursor. Four efficacy and safety trials were conducted that included more than 16,000 females 16 through 26 years of age. Half of these participants, more than 8,000 women, received the vaccine. The other half received the placebo. The vaccine was found to be highly effective. This graphic shows clinical efficacy among women with no evidence of prior or current infection with vaccine HPV types. For prevention of HPV 16 or 18 related cervical intraepithelial neoplasia 2 or 3, or adenocarcinoma in situ, shown here as AIS, there were no cases among vaccine recipients compared with 53 cases among women who received placebo for a 100% efficacy. For prevention of any CIN or AIS, there were four cases among women who received vaccine and 83 in women who received placebo for an efficacy of 95%. For prevention of genital warts, there was one case in the vaccine group and 91 cases in the placebo group for an efficacy of 99%. Some women enrolled in the vaccine trials had evidence of past or current infection with HPV types included in the vaccine or abnormal PAP tests. There was no evidence that the vaccine had efficacy against existing disease or infection, that is the vaccine had no therapeutic effect. However, prior infection with one HPV type did not diminish efficacy of the vaccine against other vaccine HPV types. Female participants in the clinical trials were grouped by age. Clinical efficacy was studied in 16 through 26 year olds. 9 through 15 year olds were also enrolled to study immunogenicity and safety of the vaccine. The younger group was not followed with PAP tests. The antibody response to the vaccine among the 9 through 15 year olds was compared to the antibody response in 16 through 26 year olds in whom clinical protection was determined. The younger participants responded to the vaccine with even higher antibody titers than the older group so clinical protection was inferred in the younger group. Males were included in the immunogenicity studies but efficacy data in males are not yet available. Additional studies are in progress now including efficacy studies in males and efficacy studies in females older than 26 years. Long-term follow-up studies are underway to look at the duration of protection. Data from these studies will be available in the next few years. HPV vaccine is currently approved by the Food and Drug Administration for females 9 through 26 years of age. The vaccine is not approved for males of any age at this time and should not be administered to females younger than 9 or older than 26 years. Merck has applied to the Food and Drug Administration for a labeling change to include women older than 26 years but this has not happened yet so for now only females 9 through 26 years should be vaccinated. The routine schedule is three doses at zero, two and six months. ACIP included information on minimum intervals between doses in its 2006 HPV statement. However, minimum intervals between doses should not be used for routine HPV vaccination. There are almost no situations where a compressed or accelerated schedule is needed. One additional HPV vaccine interval issue ACIP has not defined a maximum interval between HPV vaccine doses. If the interval between doses is longer than recommended you should just continue the series where it was interrupted. It is not necessary to add doses or restart the series because of an extended interval between doses. Remember that the minimum intervals between doses should not be used for routine vaccination. There are data that indicate very high efficacy when the three-dose HPV series is administered during a six-month period and it is at this dosing schedule that you should be using. More information about the clinical trials that led to the licensure of the vaccine is available in the package insert and in the ACIP statement. Dana? The ACIP recommendations for use of human papillomavirus vaccine were published in March 2007 but before we talk about the vaccine recommendations I am required by federal law to tell you this. Correct and consistent condom use may have a protective effect on HPV acquisition, reduce the risk for HPV associated diseases, and mitigate the adverse consequences of infection with HPV. The ACIP recommends routine vaccination of females 11 or 12 years of age with the three-dose series. This age corresponds to that of other recent recommendations for acellular pertussis and meningococcal conjugate vaccines. The vaccination series can be started as young as nine years of age at the clinician's discretion. While the recommended age for routine vaccination is 11 or 12 years there will be older females who could benefit from the vaccine. Vaccination is also recommended for females 13 through 26 years of age who have not been previously vaccinated. Vaccine should be administered before onset of sexual activity if possible but females who are sexually active should still be vaccinated. In this age group females not yet sexually active can be expected to have the full benefit of vaccination because they are not infected with HPV. Sexually active females may not have full benefit of the vaccine because they may have been already infected with vaccine HPV types. However only a small percentage of sexually active females are likely to have been infected with all four HPV vaccine types. For those already infected with one or more vaccine HPV types the vaccine would provide protection against disease caused by the other vaccine HPV types. So although overall vaccine effectiveness would be lower when administered to a population of females who are sexually active most females will still derive some benefit from vaccination. There are a variety of what ACIP calls special situations for HPV vaccine. Vaccine can be administered to females 26 years of age or younger with an equivocal or abnormal PAP test, a positive HPV DNA test meaning they are currently infected or those with genital warts. However these women should be informed that the vaccine will have no effect on existing disease or infection. Females 26 years of age or younger who are lactating and breastfeeding or who are immunocompromised may be vaccinated. However the vaccine is not recommended for pregnant women. Although HPV is an inactivated subunit vaccine ACIP prefers a conservative approach to the vaccination of pregnant women. Initiation of the vaccine series should be delayed until after completion of the pregnancy. If a woman is found to be pregnant after initiating the vaccination series completion of the series should be delayed until after the pregnancy. If a vaccine dose has been administered during pregnancy there is no indication for intervention. A vaccine in pregnancy registry has been established and women vaccinated during pregnancy should be reported. The telephone number is in the vaccine package insert. Yabba? HPV vaccine has a limited number of contraindications and precautions. As with all vaccines HPV vaccine should not be administered to persons with a history of a severe allergic reaction to a vaccine component or following a prior dose. Vaccination of persons with moderate or severe acute illness should be deferred until the acute illness improves. Adverse reactions following HPV vaccine are similar to most other inactivated vaccines. In the pre-licensure clinical trials local reactions such as pain, redness or swelling were reported in 25 to 84 percent of recipients. A temperature of 100 degrees fahrenheit in the 15 days after vaccination was reported in 10 percent of vaccine recipients. A similar proportion of placebo recipients reported a temperature. No serious adverse events have been associated with HPV vaccine. Local reactions increased in frequency with increasing doses. However reports of fever did not increase significantly with increasing doses. The vaccine adverse event reporting system is being carefully monitored for HPV vaccine reports like it is for all new vaccines. Fares has detected an increase in the number of reports of syncope following vaccination. Many of these events have followed administration of HPV vaccine. Providers need to be aware that syncope can occur after vaccination and may be more common among adolescents and young adults. Be sure to have the person sit down when being vaccinated. You should also consider a 15 to 20 minute observation period after vaccination as discussed in the 2006 general recommendations on immunization. HPV vaccine is a major breakthrough in public health but it's not the final solution to cervical cancer prevention. The vaccine HPV types are responsible for about 70 percent of cervical cancers so cervical and other cancers will continue to occur among vaccinated women because of the 30 percent of oncogenic HPV types not included in the vaccine. That is why continued cervical cancer screening is critical. Cervical cancer screening recommendations have not changed for females who receive HPV vaccine. HPV types in the vaccine are responsible for about 70 percent of cervical cancers. Females who are vaccinated could subsequently be infected with a carcinogenic HPV type not in the quadrivalent vaccine. Also females who are sexually active prize of vaccination could have been infected with a vaccine type HPV before vaccination. Healthcare providers who are administering HPV vaccine should take the opportunity to educate women about the importance of cervical cancer screening at intervals recommended by national organizations. Gardasil is packaged in single-dose vials and syringes. It should be stored in the refrigerator with other inactivated vaccines. However, it is sensitive to light which we usually associate with live vaccines. Be sure to keep the vials or syringes in the original boxes with the tops closed until ready for use. The vaccine should be used promptly after removal from the refrigerator. The availability of a vaccine to prevent human papillomavirus and the sequelae of persistent infection is a major advance in preventive medicine. We look forward to complete implementation of this new vaccine and the improvement in women's health that will accompany it. Thank you Yabo. We receive a lot of questions from providers about HPV vaccine and I guess I'll go through some of them right now. I'll pose the first question to Donna. It has to do with minimum intervals. Providers have used minimum intervals in the past and I think with this vaccine in particular are there any instances where it's really justified? Well I mean I think if you know there was a risk that you weren't going to be able to get all three doses in and maybe somebody was going to be traveling and gone for a long time you know it might be something like that but just for convenience to try to scrunch them together and get them in we really do not recommend that at all. And remember that if you are concerned that someone is going to age out and not finish the series say you start vaccinating someone who's 26 and they're going to turn 27 before you finish the series you can you can finish it that's okay. What's not recommended is to start the series at 27 not at this time because it's not approved you know beyond 26 but you can finish a series at 27 that you've started and um and you don't you know there I think there also was some concern that if they didn't get all the doses in you know quickly that you would end up going too long and have to start the series over and that's not true you know there there's no maximum intervals you don't have to restart the series you would just pick up where you left off and finish it. So try as much as possible to stick as closely to those those recommended intervals in that six-month time frame because that's where the best data is on getting the results that we want with this vaccine. Excellent I think another point that just to make again providers are asked HPV vaccine only recommended up through 26 years why is that exactly why we cut it off there a lot of providers are really interested in knowing more about that. Right Andrew and really this is similar to other vaccines as well why is it that they are only recommended for certain ages well it's really based on the pre-licensure studies and the ages of the groups that are studied and as Donna already mentioned with HPV vaccine if someone were to start this even though it was only licensed till 26 years old if someone were to start the series at 26 and didn't finish they could complete it after the age of 26. So really this is the concerns. Thank you very much Yabo. Thank you Donna. This brings us to the close of this session of epidemiology and prevention of vaccine preventable diseases. We would like to remind you of resources that you can use to get more information or to contact us. Here's the companion book for this program. The public health foundation is the sole source for a printed copy. The book costs $35 plus shipping and handling and is a useful resource for any office that administers vaccine to persons of any age. You can contact the public health foundation through their toll-free number at<PHONE_NUMBER>. You can also order materials online from their website at bookstore.phf.org. If your patients or their parents have immunization related questions you can refer them to the CDC Info Contact Center. You can reach the contact center toll free at 800 CDC Info. The CDC Info Contact Center is staffed 24 hours a day seven days a week. If you or your staff have questions you should direct them to us at the National Center for Immunization and Respiratory Diseases by email. Our email address is nipinfo.cdc.gov Throughout this program we've mentioned additional immunization resources available to you on the updates and resources web page. The address is www.cdc.gov front slash vaccines. Click on education and training then the self-study link. Choose this program from the list to find all the materials we've discussed during this program. We want you to have the most current immunization information at your fingertips. An easy way to do this is to have the information available on your computer. We've compiled all the current ACIP statements, vaccine information statements, the course text, and much more on a CD called Immunization Works. The CD is a great way to have all your current immunization information together in one place. Immunization Works is distributed free of charge by the CDC. The updates and resources web page has a link to order it. Continuing education credit is available for viewing this program. Details and instructions can be found in the continuing education chapter of the DVD or on the updates and resources web page. Thank you for joining us for this session of Epidemiology and Prevention of Vaccine Preventable Diseases. Please join us for other programs in this series when we discuss specific vaccine preventable diseases and the vaccines to prevent them. Until then, goodbye.


Remember a Hallmark card when you carry enough to send the very best. On the Hallmark Playhouse, it's known authors. They distinguish novelists. Mr. James... Good evening, ladies and gentlemen. This is James Hilton. Tonight on our Hallmark Playhouse, we tell you a story which is part of our history, Evangeline, which Longfellow wrote just over a hundred years ago. Many of us remember it from our early days, and there is indeed a springtime freshness in the lilt of its lines. But it's the story itself that has always been popular. The tale of Evangeline, which, with its simple pathos, stands as a tribute from one of our greatest poets to those early days when America was not yet a country, but was already the proving ground of heroes and heroines. Such a heroine was Evangeline. And to play her part, we have chosen one of Hollywood's loveliest and most distinguished actresses and her Academy Award winner, Joan Fontaine. And now here is Frank Goss from the Makers of Hallmark Cards. One of the particular joys of Christmas is sending and receiving Christmas cards. While the pleasure Christmas cards bring can ever be measured, isn't it good to know that Hallmark cards are priced the same this year as they were last year? And the year before? And the year before that? And that the quality of Hallmark cards has constantly improved throughout the years. Yes, today, just as for many Christmas seasons, that Hallmark on the back of your card is looked for and welcomed. It tells your friends you cared enough to send the very best. And now Hallmark Playhouse presenting Henry Wadsworth Longfellow's Evangeline, starring Joan Fontaine. Evangeline cannot contain the spirit and soul of Evangeline. Her travels are over now. The search is done. And she smiles faintly as she rests by the warmth of her heart in the friendly city of Quakers. Her eyelids close and her mind slips back along the years to times long past. And the troubled events of her childhood in the miracle of remembering take on the measure of poetry. The forest primeval, the memory of pines and the hemlocks, bearded with moss and in garments green, indistinct in the twilight, stand like droids of eld with voices sad and prophetic. In the Acadian land, on the shores of the basin of Mina, distant, secluded, still, our little village of Grand Prairie lay in the fruitful valley. Good evening, Father Felicia. Good evening to you, Mr. Belfontaine. I pray that all things go well on your farm. My harvest is good. My daughter is beautiful. And my prayers of thanksgiving rise to the heavens like the straight blue smoke from my chimney. That is the voice of my father, the wealthiest farmer of Grand Prairie. Neither locks had we to our doors nor bars to our windows. Our dwellings were open as day and the hearts of their owners. There the richest was poor and the poorest lived in abundance. Evangeline. Yes, Father. There's a young gentleman here to see you. Gabrielle. I believe that is the young fellow's name. Oh, Gabrielle. Hello, my love. Gabrielle, have you asked him? This lad brings me the most preposterous news. He says he's in love with you. And shall be, as long as I live. He has the odd notion you might have him for a husband. Is this true, Evangeline? If my father will give us his blessing. My blessing? How can I give you again what you have had all your lifetimes?  Your father, Gabrielle, is my oldest friend. And Evangeline is the image and the soul of her mother. What could please an old man more than to add his dowry and blessing to those the Lord has already blessed? Thank you, Father. Thank you, Monsieur Del Pontin. Who is there? Come in. The door is not locked. I wish to speak with a man called Del Pontin. I am Benedict Del Pontin. I am Captain Monison in the service of his Britannic Majesty. Oh, stranger indeed. But no less welcome. What is your message, Captain? I prefer to speak with you alone. As you wish. These children do not demand our company. Go, Gabrielle, give your bride a gift of moonlight. Come, Evangeline. Good evening to you, sir. Good night, my child. Do not light that man. His eyes are as cold as iron. You are trembling, my love. Why is he here? Why does a British captain want to speak with my father? Look. A dozen of them. They are warships. Gabrielle, the moonlight gleams on the canals. When did they come? It is evil, Gabrielle. I am afraid. It is now we have asked ourselves why do these strange vessels lie at anchor in our harbor? Today we shall know. Captain Monison has asked that the men of Grand Prix gather here in the village church that he may speak to us all. The men alone? Without our wives and families? That is the captain's request. Why are they here, Good Benedict? What do they wish from us? Listen, the troops are coming ashore. Soon we will know. And after the meeting, my friends, all of you, the entire village of Grand Prix, all are invited to a feast, celebrating the betrothal of Gabrielle, the blacksmith's son, to my daughter, Evangeline. Me? I am a gentleman. In France and England, all enemies of the British craft, things in your property, those as prisoners of war will be transported by the ships in your harbor to other lands. You will tear us from our homes? They honor you, our prisoners of the crown. Monson of arms, we tell. Until a more peaceable spirit descends upon you. What madness has seized you, my children? Cheese, my friends, hear the words of Father Felicia. Have you so soon forgotten all lessons of love and forgiveness? This is the house of the Prince of Peace. And would you profane it with violence and hatred? Let us repeat the prayer of the master. Oh, Father, in heaven, forgive them, for they know not what they want. Long in the house of my father, the cloth had been spread on the table. There stood the bread for the feast, and the honey fragrant with wildflowers. Over the darkening fields, I walked to the gloom of the churchyard. All was silent within, and in vain at the door and the windows I stood and I listened. No answer came from the graves of the dead, nor the gloomier grave of the living. Slowly at length I returned to the tenetless house of my father. Empty and drear was each room, and haunted with pantoms of terror. In the dead of the night I heard the disconsolate rain fall. Keenly the lightning flashed, and the voice of the echoing thunder told me that God was in heaven and governed the world He created. The sun had risen and set, and now, on the fifth day, we came, as the captain commanded, the Acadian women and children, driving in ponderous wagons our household goods to the seashore. Move along now. Get ready to board ship. Gabrielle! Gabrielle! Evangeline! Evangeline! Oh, my love. Oh, how weary you've looked up here. There alone has sustained us. O be of good cheer, my dear one, for if we love one another, nothing, nothing can harm us. You were there. Get into this boat. I'm coming with you, Gabrielle. No more room. Wait for the next boat. No! You two not separate us. We're engaged to be married. Prisoners of war will do as they are commanded. Evangeline, we'll find each other, Evangeline. Goodbye, my dearest one. Goodbye, my dearest one. Just good-bye. We'll turn to the second act of the dangelion, starring Joan Fontaine. How many of the friends on your Christmas card list have you seen in the past two months? The past year. Some perhaps you haven't seen in five years. And this once a year Christmas greeting is your only contact with them. Yet these seldom seen friends are often the dearest ones on our entire list and help make Christmas the wonderful season it is. Then doesn't it seem only the gracious thing to do to make sure that the Christmas card you send truly represents you, you at your best, expressing your Christmas wishes in a beautiful manner, reflecting your good taste in a way all can appreciate? That's what you can do if you make sure the card you select is a Hallmark card. Whether you choose from the Hallmark album and have your name imprinted, whether you select from the many Hallmark boxed collections, or whether you prefer individual cards from the Hallmark display counters, you can be sure your card will be received with the added pleasure reserved for things we value. Because like sterling on silver, that Hallmark on the back of a card is a sign of quality, telling your friends you cared enough to send the very best. Now back to James Hilton and the second act of a Vangeline, starring Joan Fontaine. The Acadian lovers were carried and on a falling tide, the freighted vessel set sail, with all its household goods into exile. Scattered on separate coasts, the Acadians landed, some to the shores of the north and some to the southern savannas, friendless, homeless, hopeless, they wandered from city to city. Among them was seen at last a maiden of reverent spirit, seeking the face that had smiled on her, searching the faces of strangers for the smile of the one who had loved her. Gabriel? Have you seen him? He was with Basil the blacksmith and both have gone to the prairies. But where? Where in the prairies? Ask to the west. Beg you to try to remember for the sake of old times in Acadia, when did you see him and where? A year ago it was, or more. He passed this way bound for the lowlands of Louisiana. What was his destination? Did he name a village a city? The only name that he uttered was the whispered name of Evangelion. Mother Felicia. Evangelion, my dear child. I look into your face, good father, and I seem to see the meadows of Grand Prey. Not as you saw them in summer, but touched with the autumn frost. Your father, good Benedict, is he well? Acadia was his heart. How long could he live with it taken from him? I'm sorry, my child. But, Gabriel, your husband, is that you? Oh, father, the marriage flowers have never been spoken. What? I have not seen my Gabriel since we were parted on the seashore. My love is wasted in air, having no soul it can cling to. Thought not of wasted affection? Affection never was wasted. My daughter, if it does not enrich the heart of another, its waters returning back to their springs like a rain of cold of refreshment at which the fountain sends forth returns again to the fountain. Father Felicia, will you help me find Gabriel? I cannot turn back from my labor of love where my heart is gone, where follows my hand and my footstep.  Together with heavenly guidance we will accomplish your work of affection. The recipe floated our cumbersome boat. Soon we were lost in a maze where the towering boughs of the Cyprus met in an arch overhead. My heart was sustained by a vision that beckoned beyond through the moonlight. Through these shadowy aisles had Gabriel wandered before me and every stroke of the hour now brought him nearer and nearer. I think says in my heart that Gabriel's soul is near me. A foolish dream. Trust to thy heart, my child. Gabriel truly is near you. Do you know, Father? Not far away to the south with other towns of Samoa and some Martins. There the long wandering bride shall be given at last to her bridegroom. Gabriel gone. Only today he departed. Your boats must have passed in the night on the river. Gabriel. A moody and restless longing for his promised bride that I sent him away. Where? Where did you send him? Up the Indian trails to the Ozarks. Hunting for furs and for beaver. Be a good cheer, Evangeline. We will follow the fugitive lover. Oh, Gabriel, my blight. Are you so near? And yet I cannot behold you. Are you so near? And yet your voice did not reach me. Patience, my child. Tomorrow. Tomorrow? Day after day with our Indian Guides we travel the forest, followed his flying steps and thought each day to ought take him. There. There is the smoke of his campfire clean in the morning air. But at nightfall when we reached the place we found only embers and ashes. You will never find him. Why do you say that? I know. I know. How do you know? What tribe are you? I am of the Shawnee people. And there is a legend among us of an Indian made in as foolish as you are. Foolish? Am I foolish? Foolish as the bride of Maui. What happened to her? She died in anguish. By starlight she pledged herself to Mois the bridegroom of snow. But in the hot sunrise her snowman vanished flowing slowly into the waters below the earth. How could she find him who was not? Am I pursuing a phantom like Mois the vanishing bridegroom? Is it endless the trail with no lover no love with the ending of the long sad years flowed on till at last I came to this delightful land which is washed by the Delaware waters guarding in silvan shades the name of Penn the apostle. Good evening to thee Sister Evangeline. I thank thee sir. God bless thee. Something at least the streets of this city something that speaks to my heart and leaves me no longer a stranger. My ear is pleased with the friendly thee and thou of the Quakers. For it recalls the past the old Acadian country where all men were equal and all were brothers and sisters. This is the year of the plague the year of the plague and the pestilence. Night after night I have worked in the house of the sisters of mercy voicing the feverish lip and cooling the brow of the stricken.  Here let me raise your head my friend and my beloved Evangeline Prime even and still the love that it sheltered sleeps in my heart deep in my heart is his image clothed in the beauty of love and youth as I long to behold him into my thoughts of Gabriel time enters not for it is not as from the mountains top the rainy mists of the morning roll away and afar we behold the landscape below us so fell the mists from my mind and I saw the world far below me dark no longer but all illumined with love and the pathway which I had climbed so far lying smooth and fair in the distance for thy merciful bounties and blessings Oh father in heaven I thank Thee and will return in a moment designed to express your Christmas wishes in a beautiful manner and yet priced to fit even the most limited budget that's how you'll describe the many different hallmark Christmas cards you can buy in convenient boxed collections many of these hallmark boxes are priced at only one dollar so you see it isn't necessary to buy expensive cards in order to be sure your cards have that hallmark on the back denoting quality in fact some boxes as low as one dollar have 22 and 25 hallmark Christmas cards in them then there are other boxed collections with designs by Norman Rockwell Winston Churchill, Grandma Moses Herb Olson and other outstanding hallmark gallery artists all are beautifully made in the hallmark tradition of craftsmen who for years have designed cards with but one thought in mind to give you a card you'll be proud to send and one that will be received with pleasure so remember look for hallmark on the cover of the box if you want your friends to see that hallmark on the back of the card you send the hallmark that tells them you cared enough to send the very best here again is James Hilton thank you for being with us tonight Joan you gave us a memorable and moving Evangeline I'm glad you liked it Mr. Hilton it's always been a favorite of mine in fact when I heard you were doing the story on hallmark play house tonight I cut short back to Hollywood well we're certainly glad you did Joan tell me did you have a nice trip in the east oh indeed I did and I saw something that reminded me of all of you what was that a sign in the greeting card department reminding everyone that to arrive overseas in time for Christmas cards should be mailed on November 15th and I said to myself I'm sure Frank Goss will be reminding our hallmark play house listeners of that tonight well as a matter of fact I was planning on doing everything myself Christmas cards and in fact all Christmas mail for service men and women should be sent by November 15th if sent regular mail and by December 1st if sent air mail and to our listeners while we hope your cards will have that hallmark on the back the important thing is that the men and women overseas received lots of Christmas mail from home you'll do your part won't you thank you Joan I'm sure our hallmark play house audience will and now I'd like to tell you about our story it's a famous book and we've chosen a rising and exciting star our story will be that wonderful adventure classic Jules Verne's 20,000 Leagues Under the Sea and to play the leading role Hollywood's young romantic star Louis Jourdan our hallmark play houses every Thursday our producer director is Bill Gay our music is composed and conducted by David Rose and our story tonight was dramatized by Lawrence and Lee until next Thursday then this is James Hilton saying good night to send the very best Joan Pontein can currently be seen in the Paramount picture darling how could


The first question is from Michael Gee, can going to failure be beneficial every once in a while? If so, how often? So personal story, so when I was a kid and I started working out, I followed the routines, the bodybuilding routines of the bodybuilders of the 90s and of the kind of routines that Arnold Schwarzenegger used to write about. And of course he was one of the most well-known bodybuilders who competed in the 70s. And so my routines were high volume, lots of sets, 15 sets per body part. And I did that for a while, but right around the age of about 15 and a half, maybe 16, my body plateaued really, really hard. Then I found a book, it was actually advertised in one of the bodybuilding magazines I was reading. And it was called Heavy Duty. And it had a picture of Mike Menser on it. Now, Mike Menser. Duty. Thanks, Justin. I was waiting for you to say that. Yes. Can't help it, dude. I can't, well. Yeah. Now, Mike Menser, it was this really impressive looking bodybuilder from the 70s and 80s. Super, super smart dude. So he's a really smart guy. And in the book he talks about training to failure. He said that, you know, there's a signal, there's a kind of like a trip wire that you hit when you work out that sends the muscle building process in motion. He thought it was intensity that did that. So he said, we'll just go to failure so that we know we hit that signal. But to offset the intensity, he only had people doing one set per body part once a week, super low volume, literally. It was like one exercise for chest, one for shoulder, one for back and so on. And I didn't do that again until the following week. Well, believe it or not, I got great response. Now it lasted about a couple of months and then I plateaued super hard again. But I did learn that, you know, that there is some value to manipulating some of these factors. But failure for most people is just too much. It's just too much intensity. Cause then later on what I learned was not trained to failure more often. I just got more consistent results, always. And for my clients, I almost never train them to failure. And it doesn't impede the following workout. No. That's the thing that I think where I really started to connect it is you get so sore, and I'm sure everyone's been in this position where you've trained so hard. And let's say I had plans that I was training Monday, Wednesday, Friday this week. And let's say I'm running a full body routine and I just crushed squats on Monday. And then Wednesday rolls around and I'm still, I'm limping in cause it's the second day after a too hard of a workouts when it's worse anyways. So here I am, I'm supposed to be lifting again on squats and my legs, I can barely walk. I don't care what you say. Like that's going to hinder that workout. You're not going to be as strong if you're still recovering from how much damage you did on Monday. And so when I backed off of that and I wasn't doing as much damage, it allowed me to not only be more frequent about it, but then also to push myself at a more even consistent rate versus this, these high peaks and lows, right?  Yeah, and intensity is much, it's easier to overdo intensity than almost anything else. It's true. I could literally take a deconditioned person off the street, bring him into our studio and I could have them do leg exercises every single day. So long as the intensity is appropriate, they can do that. I could take someone off the streets at decondition, take them through one set of squats to failure and crush them and destroy them, completely destroy them. So for most people, most of you listening right now, stop your sets about two reps short of failure. If you're advanced going to failure is a tool that you can utilize, but I would even suggest you use that infrequently.